Ascendis Pharma (ASND) director details warrants, RSUs and shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Ascendis Pharma A/S director Lisa Morrison filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units tied to ordinary shares and American Depositary Shares. She holds 1,572 ordinary shares directly, fully vested warrants over multiple strike prices, and several RSU awards that begin vesting on March 1, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Morrison Lisa
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Warrants | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 5,105 shares (Direct);
Restricted Stock Units — 1,374 shares (Direct);
Ordinary Shares — 1,572 shares (Direct)
Footnotes (1)
- Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share. The warrants are fully vested and currently exercisable. The restricted stock units vest on March 1, 2027 and have no expiration date. Each restricted stock unit represents a contingent right to receive one ADS. The restricted stock units vest in two equal annual installments beginning on March 1, 2027. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
